Centre of Evidence of Dermatology Best practice guidelines

Guidelines hidradenitis suppurativa Updated on august 2019


The information provided by this website comes from sources deemed reliable. However, the French Dermatology Society recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The French Dermatology Society cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.


Back to decision-making tree Print last updated on 04/11/2020

When there is no need for contraception, it is not recommended to prescribe an oestrogen-progestin combination with the aim of treating HS.

In other cases, when a female patient requests contraception, a gynaecologist should be consulted.

In the case of menstrual-regulated flare of HS and/or suspicion of PCOS (Polycystic Ovary Syndrome) associated with HS, a gynecological or endocrinological opinion will be proposed.

  • Was this article helpful to you?
  • Your opinion counts!

    This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.

read comorbidities

Centre of Evidence of Dermatology Centre of Evidence of Dermatology logo
10 cité Malesherbes
Work +33.1 43 27 01 56
Fax +33.1 43 27 01 86